CNBC has posted the following Reuters story: "Valeant Pharmaceuticals is reaching out to potential buyers for its specialty contact lens manufacturing division, Paragon Vision Sciences, amid scrutiny from the Federal Trade Commission, according to two people familiar with the matter.
"A sale of Paragon, which Valeant's Bausch & Lomb unit purchased earlier this year for an undisclosed sum, would deal a blow to the specialty pharmaceutical company's attempt to consolidate the market for gas permeable contact lenses, a type of rigid lens popular among people with keratoconus, a thinning disorder of the cornea, among other eye diseases. The FTC [Federal Trade Commission] has been investigating Valeant for potentially cornering a portion of the lens market." Read more.
No comments:
Post a Comment